

Supplementary Table 3: Percentage (95% CI) of subjects with anti-LPS antibody titer >121 EU after vaccination*

Trial	Vaccine group		28 days after 1 st vaccination	28 days after 2 nd vaccination	28 days after 3 rd vaccination	6 months after last vaccination
1	0-059/1 IM	%	0%	13%	25%	25%
		95% CI	(0-37)	(0-53)	(3-65)	(3-65)
		n	8	8	8	8
	0-29/5 IM	%	22%	33%	56%	22%
		95% CI	(3-60)	(7-70)	(21-86)	(3-60)
		n	9	9	9	9
	1-5/25 IM	%	75%	75%	86%	71%
		95% CI	(35-97)	(35-97)	(42-100)	(29-96)
		n	8	8	7	7
	2-9/50 IM	%	57%	50%	67%	50%
		95% CI	(18-90)	(12-88)	(22-96)	(12-88)
		n	7	6	6	6
5-9/100 IM	%	44%	63%	50%	38%	
	95% CI	(14-79)	(24-91)	(16-84)	(9-76)	
	n	9	8	8	8	
Placebo IM	%	0%	0%	0%	0%	
	95% CI	(0-37)	(0-37)	(0-37)	(0-41)	
	n	8	8	8	7	
2	0-0059/0-1 ID	%	0%	0%	0%	0%
		95% CI	(0-60)	(0-60)	(0-60)	(0-60)
		n	4	4	4	4
	0-059/1 ID	%	0%	0%	0%	0%
		95% CI	(0-46)	(0-52)	(0-46)	(0-46)
		n	6	5	6	6
	0-59/10 ID	%	20%	20%	20%	0%
		95% CI	(1-72)	(1-72)	(1-72)	(0-52)
		n	5	5	5	5
	0-29/5 IN	%	0%	0%	0%	0%
		95% CI	(0-60)	(0-60)	(0-60)	(0-60)
		n	4	4	4	4
	1-2/20 IN	%	17%	17%	17%	17%
		95% CI	(0-64)	(0-64)	(0-64)	(0-64)
		n	6	6	6	6
	4-8/80 IN	%	0%	0%	0%	0%
		95% CI	(0-46)	(0-52)	(0-46)	(0-46)
		n	6	5	6	6
	0-29/5 IM	%	17%	17%	33%	17%
		95% CI	(0-64)	(0-64)	(4-78)	(0-64)
		n	6	6	6	6
	Placebo	%	0%	0%	0%	0%
		95% CI	(0-23)	(0-23)	(0-25)	(0-26)
		n	14	14	13	12

CI =confidence interval. Vaccine groups are quantified as per µg of OAg/µg of protein. ID= intradermal. IN= intranasal. IM=intramuscular.